Gene editing has begun to be tested in clinical trials, using CRISPR-Cas9 and other technologies to directly edit DNA inside people's cells, and multiple trials are recruiting or in the planning stages. A new study raises a note of caution, finding that person-to-person genetic differences may undercut the efficacy of the gene editing process or, in more rare cases, cause a potentially dangerous "off target" effect.
The study adds to evidence that gene editing may need to be adapted to each patient's genome, to ensure there aren't variants in DNA sequence in or near the gene being targeted that would throw off the technology. Findings appear in the Proceedings of the National Academy of Sciences .
"Humans vary in their DNA sequences, and what is taken as the 'normal' DNA sequence for reference cannot account for all these differences," says co-corresponding author. "We recommend that common variation be taken into account in designing targeting systems for therapeutic editing, to maximize efficacy and minimize potential safety concerns."
The study analyzed 7,444 previously published whole-genome sequences. Based on a list of about 30 disease-related DNA targets that researchers are interested in altering through gene editing, the researchers made a second list of nearly 3,000 guide RNAs (gRNAs). These are bits of genetic code that have been developed to direct CRISPR-Cas9 enzymes to the right editing location on or adjacent to the target, like the address on an envelope.
The team then looked to see whether any of the 7,444 individuals carried DNA sequence variants ("letter changes" or insertions/deletions) in the areas the gRNAs are looking for.
"If there are genetic differences at the site that CRISPR reagents are targeting for therapy, you are at risk for decreased efficacy or treatment failure," explains study lead. "A difference in just a single base pair can cause a decrease in binding efficiency due to a mismatch with the guide RNA. Overall, this can cause a reduction in treatment efficacy."
The team found that such occurrences in the genome are not uncommon; about 50 percent of the analyzed gRNAs had the potential to be affected by variants at their target sites. In a few cases, the team found genetic variants that cause DNA sequences in the genome to more closely match a gRNA that could potentially draw it to the wrong place -- resulting in an edit of a gene or other DNA region that's not meant to be targeted.
"In rare cases, there was the potential to create very potent 'off-target' sites - where CRISPR reagents could bind and cut where they're not intended to," says the study lead. "If an off-target effect happens to be in, say, a tumor suppressor gene, that would be a big concern."
Although the study looked at CRISPR-Cas9 gene editing, the researchers believe their findings extend to other gene-editing tools such as zinc-finger nucleases (ZFN) and TAL effector nucleases.
Patients' individual genomes may affect efficacy, safety of gene editing
- 552 views